pertuzumab
Showing 1 - 25 of 142
Healthy Men Trial in Moscow (Pertuzumab, Perjeta®)
Not yet recruiting
- Healthy Men
- Pertuzumab
- Perjeta®
-
Moscow, Russian FederationCentral Clinical Hospital "RZD-Medicina"
Apr 11, 2023
Metastatic Breast Cancer Trial (BDC-1001, Pertuzumab)
Not yet recruiting
- Metastatic Breast Cancer
- BDC-1001
- Pertuzumab
- (no location specified)
Jul 12, 2023
Metastatic HER2-Positive Breast Cancer Trial in United States (Gemcitabine, Trastuzumab, Pertuzumab)
Active, not recruiting
- Metastatic HER2-Positive Breast Cancer
- Gemcitabine
- +2 more
-
Hartford, Connecticut
- +4 more
Dec 1, 2022
Breast Cancer Trial in Shanghai (Pertuzumab)
Not yet recruiting
- Breast Cancer
- Pertuzumab
-
Shanghai, Shanghai, ChinaShanghai Jiaotong University School of Medicine affiliated Ruiji
Jun 4, 2023
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease Trial in Tampa, Evanston (Radiation Therapy,
Recruiting
- HER2-positive Breast Cancer
- +2 more
- Radiation Therapy
- +2 more
-
Tampa, Florida
- +1 more
Dec 30, 2022
Breast Cancer Trial in Shanghai (Dalpiciclib, Fulvestrant, Pertuzumab)
Active, not recruiting
- Breast Cancer
- Dalpiciclib
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Oct 10, 2022
Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)
Recruiting
- Breast Cancer
- Pegylated liposomal doxorubicin
- +5 more
-
Shanghai, ChinaShanghai Pudong Hospital
Dec 11, 2022
Breast Cancer Trial in Houston (Durvalumab, Trastuzumab, Pertuzumab)
Recruiting
- Breast Cancer
- Durvalumab
- +2 more
-
Houston, TexasHouston Methodist Cancer Center
Aug 5, 2022
Breast Tumors, Malignant Tumor of the Breast Trial in Multiple Locations (Trastuzumab, Pertuzumab, Vinorelbine, Paclitaxel,
Terminated
- Breast Neoplasms
- Malignant Tumor of the Breast
- Trastuzumab
- +2 more
-
Multiple Locations, Texas19 Sites
Nov 29, 2022
Breast Cancer Trial in Shenyang (Pyrotinib, Trastuzumab, Dalpiciclib)
Not yet recruiting
- Breast Cancer
- Pyrotinib
- +7 more
-
Shenyang, Liaoning, ChinaShengjing Hospital of China Medical University
Dec 2, 2022
Esophageal Cancer, Esophageal Adenocarcinoma Trial in Amsterdam (Trastuzumab, Pertuzumab, Paclitaxel)
Recruiting
- Esophageal Cancer
- Esophageal Adenocarcinoma
- Trastuzumab
- +3 more
-
Amsterdam, NetherlandsAcademic Medical Center
Jun 18, 2022
HER2-positive Breast Cancer Trial in Tampa (biological, drug, procedure)
Recruiting
- HER2-positive Breast Cancer
- HER-2 pulsed DC1
- +4 more
-
Tampa, FloridaMoffitt Cancer Center
Oct 6, 2022
HER2 Positive Early Breast Cancer Trial in Shanghai (Docetaxel, carboplatin, Trastuzumab)
Recruiting
- HER2 Positive Early Breast Cancer
- Docetaxel
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 6, 2023
HER2-positive Breast Cancer Trial in Shanghai (SYSA1901, Pertuzumab, Trastuzumab)
Recruiting
- HER2-positive Breast Cancer
- SYSA1901
- +3 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Feb 8, 2023
Breast Cancer Trial in Boston, Ann Arbor (drug, procedure, radiation)
HER2-positive Breast Cancer Trial in Philadelphia (Atezolizumab, Paclitaxel, Trastuzumab)
Suspended
- HER2-positive Breast Cancer
- Atezolizumab
- +3 more
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Jul 5, 2022
First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer Trial (KN026, HB1801, Pertuzumab)
Not yet recruiting
- First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
- KN026
- +4 more
- (no location specified)
Apr 20, 2023
Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)
Recruiting
- Metastatic Breast Cancer
- Ipatasertib
- +2 more
-
Badalona, Barcelona, Spain
- +9 more
Oct 24, 2022
HER2-positive Breast Cancer Trial in Shenyang (ARX788, Pyrotinib maleate, Trastuzumab)
Recruiting
- HER2-positive Breast Cancer
- ARX788
- +5 more
-
Shenyang, Liaoning, ChinaShengjing Hospital affiliated to China Medical University
Jun 21, 2022
Breast Cancer Trial in Helsinki (Pertuzumab, Trastuzumab)
Active, not recruiting
- Breast Cancer
- Pertuzumab
- Trastuzumab
-
Helsinki, FinlandHelsinki University Central Hospital
Mar 15, 2022
Breast Cancer Trial in United States (Positron emission tomography (PET), Trastuzumab, Pertuzumab)
Active, not recruiting
- Breast Cancer
- Positron emission tomography (PET)
- +2 more
-
Birmingham, Alabama
- +9 more
Jan 20, 2023
Breast Cancer Invasive Trial in Shanghai (Pyrotinib, Trastuzumab, Pertuzumab)
Active, not recruiting
- Breast Cancer Invasive
- Pyrotinib
- +7 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiaotong University School of Medicine
Mar 28, 2022
HER2-positive Metastatic Breast Cancer, CNS Metastases Trial in Chicago, Boston (ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB)
Active, not recruiting
- HER2-positive Metastatic Breast Cancer
- Central Nervous System Metastases
- ATEZOLIZUMAB
- +2 more
-
Chicago, Illinois
- +1 more
Mar 14, 2022